MINT-ACYCLOVIR TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ACYCLOVIR

Pieejams no:

MINT PHARMACEUTICALS INC

ATĶ kods:

J05AB01

SNN (starptautisko nepatentēto nosaukumu):

ACYCLOVIR

Deva:

200MG

Zāļu forma:

TABLET

Kompozīcija:

ACYCLOVIR 200MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Produktu pārskats:

Active ingredient group (AIG) number: 0115506002; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2022-01-25

Produkta apraksts

PRODUCT MONOGRAPH
PR
MINT-ACYCLOVIR
ACYCLOVIR TABLETS USP
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
MINT PHARMACEUTICALS INC.
DATE OF PREPARATION:
6575 DAVAND DRIVE
JANUARY 21, 2022
MISSISSAUGA, ONTARIO
L5T 2M3
Control No. 239932
_MINT-ACYCLOVIR Product Monograph_
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3 SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
6
DRUG INTERACTIONS
..................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
..............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.............................................................12
STORAGE AND STABILITY
.........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................14
PART II: SCIENTIFIC
INFORMATION.......................................................................
15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
........................................................................................................15
DETAILED PHARMACOLOGY
....................................................................................16
VIR